Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide
December 05, 2019 08:00 ET
|
Dynavax Technologies Corporation
- Partnership at 1,700 pharmacies nationwide with special focus on people living with diabetes- People living with diabetes are two times more likely to become infected with hepatitis B virus and up...
Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed
December 03, 2019 07:00 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax to Present at the Stifel 2019 Healthcare Conference
November 07, 2019 16:05 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Announces Third Quarter 2019 Financial Results
November 06, 2019 16:05 ET
|
Dynavax Technologies Corporation
Third quarter 2019 HEPLISAV-B® net product revenue of $10.2 millionRaising revenue expectation range to $34-$36 million for full year 2019Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT ...
Dynavax to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6
October 24, 2019 16:05 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, will report third...
Dynavax to Present at the 2019 Cantor Global Healthcare Conference
September 30, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President,...
Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
August 12, 2019 16:05 ET
|
Dynavax Technologies Corporation
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax...
Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
August 08, 2019 08:00 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and...
Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock
August 07, 2019 16:12 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and...
Dynavax Announces Second Quarter 2019 Financial Results
August 07, 2019 16:01 ET
|
Dynavax Technologies Corporation
Second quarter 2019 HEPLISAV-B® net product revenue of $8.3 millionUpdated net product revenue guidance of $32-$36 million for full year 2019Conference call to be held today at 4:30 p.m. ET/1:30 p.m....